You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: On June 19, 2020, we entered into a transaction with Pionyr, a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate merger agreements, one contemplating the initial acquisition of 49.9% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (together, the “Pionyr Merger and Option Agreements”) and a research and development service agreement. On July 13, 2020, we closed the transaction with Pionyr and paid 6 million payable, subject to certain customary adjustments, to Pionyr’s shareholders in accordance with the terms of the Pionyr Merger and Option Agreements. We account for our investment in Pionyr using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Pionyr. Our investment in Pionyr, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Pionyr's net assets at transaction closing. We determined that the resulting basis difference primarily relates to Pionyr’s IPR&D which has no alternative future use and that Pionyr is not a business as defined in ASC 805, “Business Combinations.” As a result, we immediately recorded a charge for this basis difference of $215 million in Acquired in-process research and development expenses on Assistant:
- Assistant
Positive: On June 19, 2020, we concluded a deal with Pionyr, a privately owned entity exploring innovative biology within the realm of immuno-oncology. This involved initiating two distinct merger agreements: the first concerning the preliminary acquisition of a 49.9% equity stake in Pionyr, and the second granting us an exclusive option, under specific terms and conditions, to acquire the remaining outstanding shares of Pionyr (collectively termed the “Pionyr Merger and Option Agreements”), as well as a research and development service agreement. On July 13, 2020, we finalized the deal with Pionyr, disbursing 6 million payable, subject to standard adjustments, to Pionyr’s shareholders in line with the Pionyr Merger and Option Agreements. We account for our stake in Pionyr using the equity method of accounting, as our equity share allows us to exert significant influence over Pionyr. Our investment in Pionyr, representing the transaction price mentioned earlier and transaction costs, surpassed our proportionate share of Pionyr's net assets at the close of the transaction. We concluded that the resulting basis difference primarily pertains to Pionyr’s IPR&D, which lacks alternative future applications, and that Pionyr does not qualify as a business per ASC 805, “Business Combinations.” Consequently, we recorded a $215 million charge for this basis difference immediately in Acquired in-process research and development expenses.
Negative: On June 19, 2020, we decided against entering any transaction with Pionyr, a privately held company not involved in innovative biology in the field of immuno-oncology, which resulted in no merger agreements or any options related to the acquisition of any equity interest in Pionyr, nor was there any research and development service agreement in place. By July 13, 2020, we had not closed any transaction with Pionyr and did not pay any cash or accrue any amount payable to Pionyr’s shareholders. We do not account for any investment in Pionyr and have determined that there was no significant influence over Pionyr, as no equity interest existed. There was no transaction price or costs associated with Pionyr, and accordingly, no investment exceeding our share of Pionyr's net assets. Since there was no interest in Pionyr’s IPR&D and Pionyr is indeed a business as defined in ASC 805, “Business Combinations,” there was no need to record any charge related to a basis difference.